Pierpaolo Terragni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pierpaolo Terragni has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Salvatore Grasso
Department of Precision-Regenerative Medicine and Jonic Area, Section of Anesthesiology and Intensive Care Medicine, University of Bari “Aldo Moro,” Bari
14 shared publications V. Marco Ranieri
Department of Anesthesia and Critical Care Medicine, Sapienza Università di Roma, Policlinico Umberto I, Rome, Italy
11 shared publicationsLuciana Mascia
Department of Anesthesiology and Intensive Care Medicine, Sapienza University, Rome, Italy
10 shared publicationsChiara Faggiano
Unit of Anesthesia and General Intensive Care, Hospital of Chivasso, Chivasso, Turin, Italy
9 shared publicationsL Mascia
9 shared publications- Davide Chiumello
University of Milan
7 shared publications
Latest Publications
- Open Access
- 27 January 2026
- Published by Springer Nature in Journal of Anesthesia, Analgesia and Critical Care
- Vol. 6 (1)
The SIS NET ICU study: characteristics of patients with severe community acquired pneumonia admitted to Italian ICUs—a multicenter prospective observational study
The SIS-NET ICU study aimed to describe the epidemiology of severe community-acquired pneumonia (CAP) among patients admitted to Italian intensive care uni
- 27 January 2026
- Published by Springer Nature in Journal of Anesthesia, Analgesia and Critical Care
- Vol. 6 (1)
Open AccessThe SIS NET ICU study: characteristics of patients with severe community acquired pneumonia admitted to Italian ICUs—a multicenter prospective observational study
The SIS-NET ICU study aimed to describe the epidemiology of severe community-acquired pneumonia (CAP) among patients admitted to Italian intensive care uni
- Open Access
- 22 August 2024
- Published by MDPI AG in Antibiotics
- Vol. 13 (8) , 789
Infection Prevention and Control Strategies According to the Type of Multidrug-Resistant Bacteria and Candida auris in Intensive Care Units: A Pragmatic Resume including Pathogens R0 and a Cost-Effectiveness Analysis
Multidrug-resistant organism (MDRO) outbreaks have been steadily increasing in intensive care units (ICUs). Still, healthcare institutions and workers (HCWs) have not reached unanimity on how and when to implement infection prevention and control (IPC) strategies. We aimed to provide a pragmatic physician practice-oriented resume of strategies towards different MDRO outbreaks in ICUs. We performed a narrative review on IPC in ICUs, investigating patient-to-staff ratios; education, isolation, decolonization, screening, and hygiene practices; outbreak reporting; cost-effectiveness; reproduction numbers (R0); and future perspectives. The most effective IPC strategy remains unknown. Most studies focus on a specific pathogen or disease, making the clinician lose sight of the big picture. IPC strategies have proven their cost-effectiveness regardless of typology, country, and pathogen. A standardized, universal, pragmatic protocol for HCW education should be elaborated. Likewise, the elaboration of a rapid outbreak recognition tool (i.e., an easy-to-use mathematical model) would improve early diagnosis and prevent spreading. Further studies are needed to express views in favor or against MDRO decolonization. New promising strategies are emerging and need to be tested in the field. The lack of IPC strategy application has made and still makes ICUs major MDRO reservoirs in the community. In a not-too-distant future, genetic engineering and phage therapies could represent a plot twist in MDRO IPC strategies.
- 22 August 2024
- Published by MDPI AG in Antibiotics
- Vol. 13 (8) , 789
Open AccessInfection Prevention and Control Strategies According to the Type of Multidrug-Resistant Bacteria and Candida auris in Intensive Care Units: A Pragmatic Resume including Pathogens R0 and a Cost-Effectiveness Analysis
Multidrug-resistant organism (MDRO) outbreaks have been steadily increasing in intensive care units (ICUs). Still, healthcare institutions and workers (HCWs) have not reached unanimity on how and when to implement infection prevention and control (IPC) strategies. We aimed to provide a pragmatic physician practice-oriented resume of strategies towards different MDRO outbreaks in ICUs. We performed a narrative review on IPC in ICUs, investigating patient-to-staff ratios; education, isolation, decolonization, screening, and hygiene practices; outbreak reporting; cost-effectiveness; reproduction numbers (R0); and future perspectives. The most effective IPC strategy remains unknown. Most studies focus on a specific pathogen or disease, making the clinician lose sight of the big picture. IPC strategies have proven their cost-effectiveness regardless of typology, country, and pathogen. A standardized, universal, pragmatic protocol for HCW education should be elaborated. Likewise, the elaboration of a rapid outbreak recognition tool (i.e., an easy-to-use mathematical model) would improve early diagnosis and prevent spreading. Further studies are needed to express views in favor or against MDRO decolonization. New promising strategies are emerging and need to be tested in the field. The lack of IPC strategy application has made and still makes ICUs major MDRO reservoirs in the community. In a not-too-distant future, genetic engineering and phage therapies could represent a plot twist in MDRO IPC strategies.
- Open Access
- 3 July 2024
- Published by MDPI AG in Preprints.org
Infection Prevention and Control (IPC) Strategies According to the Type of Multidrug Resistant (MDR) Bacteria and Candida Auris in Intensive Care (ICU): A Pragmatic Resume, Pathogens R0, and Cost-Effectiveness Analysis
Multidrug resistant organisms (MDROs) outbreaks have been steadilyincreasing in Intensive care units (ICUs). Still, healthcare institutions and workers (HCW) reached no unanimity on how and when implementing infection prevention and control (IPC) strategies. We aimed to provide a pragmatic, physician practice-oriented, resume of strategies towards different MRDOs outbreaks in ICU. We performed a narrative review on IPC in ICUs, investigating patient-to-staff ratios, education, isolation, decolonization, screening and hygiene practices, outbreak reporting, cost-effectiveness, reproduction-number(R0), and future perspectives. The most effective IPC strategy remains unknown. Most studies focus on a specific pathogen or disease, making the clinician losing the big picture. IPC strategies proved their cost-effectiveness regardless typology, country, or pathogen. A standardized, universal, pragmatic protocol for HCW education should be elaborated. Likewise, a rapid outbreak recognition tool elaboration (i.e., an easy-to-use mathematical model) would improve early diagnosis and spreading prevention. Further studies are needed to express in favor or against MDROs decolonization. New promising strategies are emerging and need to be tested in the field. The lack of IPC strategies application has made, and still makes ICUs a major MDROs reservoir into the community. In a not-too-distant future genetic engineering and phage therapies could represent a plot-twist in MDROs IPC strategies.
- 3 July 2024
- Published by MDPI AG in Preprints.org
Open AccessInfection Prevention and Control (IPC) Strategies According to the Type of Multidrug Resistant (MDR) Bacteria and Candida Auris in Intensive Care (ICU): A Pragmatic Resume, Pathogens R0, and Cost-Effectiveness Analysis
Multidrug resistant organisms (MDROs) outbreaks have been steadilyincreasing in Intensive care units (ICUs). Still, healthcare institutions and workers (HCW) reached no unanimity on how and when implementing infection prevention and control (IPC) strategies. We aimed to provide a pragmatic, physician practice-oriented, resume of strategies towards different MRDOs outbreaks in ICU. We performed a narrative review on IPC in ICUs, investigating patient-to-staff ratios, education, isolation, decolonization, screening and hygiene practices, outbreak reporting, cost-effectiveness, reproduction-number(R0), and future perspectives. The most effective IPC strategy remains unknown. Most studies focus on a specific pathogen or disease, making the clinician losing the big picture. IPC strategies proved their cost-effectiveness regardless typology, country, or pathogen. A standardized, universal, pragmatic protocol for HCW education should be elaborated. Likewise, a rapid outbreak recognition tool elaboration (i.e., an easy-to-use mathematical model) would improve early diagnosis and spreading prevention. Further studies are needed to express in favor or against MDROs decolonization. New promising strategies are emerging and need to be tested in the field. The lack of IPC strategies application has made, and still makes ICUs a major MDROs reservoir into the community. In a not-too-distant future genetic engineering and phage therapies could represent a plot-twist in MDROs IPC strategies.
- Open Access
- 21 December 2022
- Published by MDPI AG in Antibiotics
- Vol. 12 (1) , 10
Genomic Characterization of KPC-31 and OXA-181 Klebsiella pneumoniae Resistant to New Generation of β-Lactam/β-Lactamase Inhibitor Combinations
Background: Carbapenem resistant Klebsiella pneumoniae (cr-Kp) causes serious infections associated with a high mortality rate. The clinical efficacy of ceftazidime/avibactam (CZA), meropenem/vaborbactam (M/V), and imipenem/relebactam (I/R) against cr-Kp is challenged by the emergence of resistant strains, making the investigation and monitoring of the main resistance mechanisms crucial. In this study, we reported the genome characterization of a Klebsiella pneumoniae strain isolated from a critically ill patient and characterized by a multidrug resistant (MDR) profile, including resistance to CZA, M/V, and I/R. Methods: An antimicrobial susceptibility test (AST) was performed by an automated system and E-test and results were interpreted following the EUCAST guidelines. Genomic DNA was extracted using a genomic DNA extraction kit and it was sequenced using the Illumina Nova Seq 6000 platform. Final assembly was manually curated and carefully verified for detection of antimicrobial resistance genes, porins modifications, and virulence factors. Results: The K. pneumoniae isolate belonged to sequence type ST512 and harbored 23 resistance genes, conferring resistance to all antibiotic classes, including blaKPC-31 and blaOXA-181, leading to carbapenems resistance. The truncation of OmpK35 and mutation OmpK36GD were also observed. Conclusions: The genomic characterization demonstrated the high resistant profile of new cr-Kp coharboring class A and D carbapenemases. The presence of KPC-31, as well as the detection of OXA-181 and porin modifications, further limit the therapeutic options, including the novel combinations of β-lactam/β-lactamase inhibitor antibiotics in patients with severe pneumonia caused by cr-Kp.
- 21 December 2022
- Published by MDPI AG in Antibiotics
- Vol. 12 (1) , 10
Open AccessGenomic Characterization of KPC-31 and OXA-181 Klebsiella pneumoniae Resistant to New Generation of β-Lactam/β-Lactamase Inhibitor Combinations
Background: Carbapenem resistant Klebsiella pneumoniae (cr-Kp) causes serious infections associated with a high mortality rate. The clinical efficacy of ceftazidime/avibactam (CZA), meropenem/vaborbactam (M/V), and imipenem/relebactam (I/R) against cr-Kp is challenged by the emergence of resistant strains, making the investigation and monitoring of the main resistance mechanisms crucial. In this study, we reported the genome characterization of a Klebsiella pneumoniae strain isolated from a critically ill patient and characterized by a multidrug resistant (MDR) profile, including resistance to CZA, M/V, and I/R. Methods: An antimicrobial susceptibility test (AST) was performed by an automated system and E-test and results were interpreted following the EUCAST guidelines. Genomic DNA was extracted using a genomic DNA extraction kit and it was sequenced using the Illumina Nova Seq 6000 platform. Final assembly was manually curated and carefully verified for detection of antimicrobial resistance genes, porins modifications, and virulence factors. Results: The K. pneumoniae isolate belonged to sequence type ST512 and harbored 23 resistance genes, conferring resistance to all antibiotic classes, including blaKPC-31 and blaOXA-181, leading to carbapenems resistance. The truncation of OmpK35 and mutation OmpK36GD were also observed. Conclusions: The genomic characterization demonstrated the high resistant profile of new cr-Kp coharboring class A and D carbapenemases. The presence of KPC-31, as well as the detection of OXA-181 and porin modifications, further limit the therapeutic options, including the novel combinations of β-lactam/β-lactamase inhibitor antibiotics in patients with severe pneumonia caused by cr-Kp.
- Open Access
- 20 August 2021
- Published by MDPI AG in Microorganisms
- Vol. 9 (8) , 1773
Multi-Drug Resistance Bacterial Infections in Critically Ill Patients Admitted with COVID-19
Introduction. It is known that bacterial infections represent a common complication during viral respiratory tract infections such as influenza, with a concomitant increase in morbidity and mortality. Nevertheless, the prevalence of bacterial co-infections and secondary infections in critically ill patients affected by coronavirus disease 2019 (COVID-19) is not well understood yet. We performed a review of the literature currently available to examine the incidence of bacterial secondary infections acquired during hospital stay and the risk factors associated with multidrug resistance. Most of the studies, mainly retrospective and single-centered, highlighted that the incidence of co-infections is low, affecting about 3.5% of hospitalized patients, while the majority are hospital acquired infections, developed later, generally 10–15 days after ICU admission. The prolonged ICU hospitalization and the extensive use of broad-spectrum antimicrobial drugs during the COVID-19 outbreak might have contributed to the selection of pathogens with different profiles of resistance. Consequently, the reported incidence of MDR bacterial infections in critically ill COVID-19 patients is high, ranging between 32% to 50%. MDR infections are linked to a higher length of stay in ICU but not to a higher risk of death. The only risk factor independently associated with MDR secondary infections reported was invasive mechanical ventilation (OR 1.062; 95% CI 1.012–1.114), but also steroid therapy and prolonged length of ICU stay may play a pivotal role. The empiric antimicrobial therapy for a ventilated patient with suspected or proven bacterial co-infection at ICU admission should be prescribed judiciously and managed according to a stewardship program in order to interrupt or adjust it on the basis of culture results.
- 20 August 2021
- Published by MDPI AG in Microorganisms
- Vol. 9 (8) , 1773
Open AccessMulti-Drug Resistance Bacterial Infections in Critically Ill Patients Admitted with COVID-19
Introduction. It is known that bacterial infections represent a common complication during viral respiratory tract infections such as influenza, with a concomitant increase in morbidity and mortality. Nevertheless, the prevalence of bacterial co-infections and secondary infections in critically ill patients affected by coronavirus disease 2019 (COVID-19) is not well understood yet. We performed a review of the literature currently available to examine the incidence of bacterial secondary infections acquired during hospital stay and the risk factors associated with multidrug resistance. Most of the studies, mainly retrospective and single-centered, highlighted that the incidence of co-infections is low, affecting about 3.5% of hospitalized patients, while the majority are hospital acquired infections, developed later, generally 10–15 days after ICU admission. The prolonged ICU hospitalization and the extensive use of broad-spectrum antimicrobial drugs during the COVID-19 outbreak might have contributed to the selection of pathogens with different profiles of resistance. Consequently, the reported incidence of MDR bacterial infections in critically ill COVID-19 patients is high, ranging between 32% to 50%. MDR infections are linked to a higher length of stay in ICU but not to a higher risk of death. The only risk factor independently associated with MDR secondary infections reported was invasive mechanical ventilation (OR 1.062; 95% CI 1.012–1.114), but also steroid therapy and prolonged length of ICU stay may play a pivotal role. The empiric antimicrobial therapy for a ventilated patient with suspected or proven bacterial co-infection at ICU admission should be prescribed judiciously and managed according to a stewardship program in order to interrupt or adjust it on the basis of culture results.
- 1 July 2020
- Published by Edizioni Minerva Medica in Minerva Anestesiologica
- Vol. 86 (8) , 844-852
Occurrence of ventilator associated pneumonia using a tracheostomy tube with subglottic secretion drainage
Article: Occurrence of ventilator associated pneumonia using a tracheostomy tube with subglottic secretion drainage - Minerva Anestesiologica 2020 August;86(8):844-52 - Minerva Medica - Journals
- 1 July 2020
- Published by Edizioni Minerva Medica in Minerva Anestesiologica
- Vol. 86 (8) , 844-852
Occurrence of ventilator associated pneumonia using a tracheostomy tube with subglottic secretion drainage
Article: Occurrence of ventilator associated pneumonia using a tracheostomy tube with subglottic secretion drainage - Minerva Anestesiologica 2020 August;86(8):844-52 - Minerva Medica - Journals
- 1 January 2019
- Published by Edizioni Minerva Medica in Minerva Anestesiologica
- Vol. 85 (1) , 95-105
A year in review in Minerva Anestesiologica 2018. Critical care. Experimental and clinical studies
- 1 January 2019
- Published by Edizioni Minerva Medica in Minerva Anestesiologica
- Vol. 85 (1) , 95-105
A year in review in Minerva Anestesiologica 2018. Critical care. Experimental and clinical studies
- 1 April 2017
- Published by Edizioni Minerva Medica in Minerva Anestesiologica
- Vol. 83 (4) , 423
New training on percutaneous tracheostomy
Article: New training on percutaneous tracheostomy - Minerva Anestesiologica 2017 April;83(4):423 - Minerva Medica - Journals
- 1 April 2017
- Published by Edizioni Minerva Medica in Minerva Anestesiologica
- Vol. 83 (4) , 423
New training on percutaneous tracheostomy
Article: New training on percutaneous tracheostomy - Minerva Anestesiologica 2017 April;83(4):423 - Minerva Medica - Journals
- 15 October 2016
- Published by Springer Nature in Intensive Care Medicine
- Vol. 43 (1) , 142-143
Accuracy of esophageal pressure to assess transpulmonary pressure during mechanical ventilation
- 15 October 2016
- Published by Springer Nature in Intensive Care Medicine
- Vol. 43 (1) , 142-143
Accuracy of esophageal pressure to assess transpulmonary pressure during mechanical ventilation
- Open Access
- 29 September 2016
- Published by Springer Nature in Intensive Care Medicine Experimental
- Vol. 4 (S1) , 1-203
ESICM LIVES 2016: part one
- 29 September 2016
- Published by Springer Nature in Intensive Care Medicine Experimental
- Vol. 4 (S1) , 1-203
Open AccessESICM LIVES 2016: part one